- Molecular NameNalidixic Acid
- SynonymNA
- Weight232.239
- Drugbank_IDDB00779
- ACS_NO389-08-2
- Show 3D model
- LogP (experiment)1.41
- LogP (predicted, AB/LogP v2.0)0.94
- pka6.0
- LogD (pH=7, predicted)-0.03
- Solubility (experiment)0.1 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.88
- LogSw (predicted, AB/LogsW2.0)0.19
- Sw (mg/ml) (predicted, ACD/Labs)0.7
- No.of HBond Donors1
- No.of HBond Acceptors5
- No.of Rotatable Bonds2
- TPSA70.5
- StatusFDA approved
- AdministrationN/A
- PharmacologyThe first of the synthetic quinolone antibiotics.
- Absorption_value90.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability60.0
- Protein binding93.0
- Volume of distribution (VD)0.4 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic. 30% of administered dose is metabolized to the active metabolite, hydroxynalidixic acid. Rapid conjugation of parent drug and active metabolite to inactive metabolites. Metabolism may vary widely among individuals. In the urine, hydroxynalidixic acid represents 80 to 85% of the antibacterial activity.
- Half lifenalidixic acid and the 7-hydroxy metabolite about 7 h; increased in renal failure to about 20 h.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityToxic psychosis, convulsions, increased intracranial pressure, or metabolic acidosis may occur in patients taking more than the recommended dosage. Vomiting, nausea, and lethargy may also occur following overdosage.
- LD50 (rat)LD50=1160 mg/kg
- LD50 (mouse)LD50=572 mg/kg